Evidence map›Paper›PMID 35489029›Full record

ArticleJournal of clinical psychopharmacology

Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.

Mohamed Mohamoud, Qi Chen, David Croteau, Carmen Cheng, Keith Burkhart, Donna A Volpe, Cindy Kortepeter, Dorothy Demczar, Marc Stone

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical psychopharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. The epidemiology and phenomenology of non-antipsychotic-induced dystonia: a hybrid systematic-narrative review.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Pooled it
  2. Drug Interactions With Excessive Daytime Sleepiness Treatments.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mohamed MohamoudFrom the Division of Pharmacovigilance, Office of Surveillance and Epidemiology.
Qi ChenDivision of Psychiatry, Office of New Drugs.
David CroteauFrom the Division of Pharmacovigilance, Office of Surveillance and Epidemiology.
Carmen ChengFrom the Division of Pharmacovigilance, Office of Surveillance and Epidemiology.
Keith BurkhartDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Donna A VolpeDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Cindy KortepeterFrom the Division of Pharmacovigilance, Office of Surveillance and Epidemiology.
Dorothy DemczarDivision of Psychiatry, Office of New Drugs.
Marc StoneDivision of Psychiatry, Office of New Drugs.
Center for Surveillance, Epidemiology, and Laboratory Services · US

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

PURPOSE/

backgroundAcute hyperkinetic movement disorders have been reported with the concomitant use of attention-deficit/hyperactivity disorder (ADHD) stimulants and antipsychotics in children and adolescents. We analyzed postmarketing reports of suspected acute hyperkinetic movement disorder associated with concomitant use of ADHD stimulants and antipsychotics. METHODS/PROCEDURES: We searched for postmarketing reports of acute hyperkinetic movement disorders associated with concomitant use of ADHD stimulants-antipsychotics in the US Food and Drug Administration Adverse Event Reporting System through December 6, 2019. PubMed and EMBASE were also searched for acute hyperkinetic movement reports with the concomitant use of ADHD stimulants-antipsychotics through January 13, 2020. FINDINGS/

resultsWe identified 36 cases resulting in acute hyperkinetic movement disorder associated with the concomitant use of ADHD stimulants-antipsychotics, 19 of which were also identified in the medical literature. From an ADHD stimulant perspective, methylphenidate products accounted for the largest number of cases (n = 23 [64%]), followed by amphetamine products (n = 9 [25%]) and atomoxetine (n = 4 [11%]). From an antipsychotic perspective, all 36 cases were reported with second-generation antipsychotics, particularly risperidone (n = 20 [56%]). Most of the cases were reported in boys (n = 31 [86%]) aged 6 to 12 years (n = 27 [75%]). Approximately 53% of the cases reported a time to onset within 24 hours of the drug change. Acute dystonic reactions (n = 27 [75%]) were the most frequently reported movement disorder. IMPLICATIONS/

conclusionsAs outlined in changes to the US prescribing information for all methylphenidate and risperidone products, health care professionals should be aware that changes to this combination may be associated with a pharmacodynamic drug-drug interaction resulting in acute hyperkinetic movement disorder.

Indexed as

Antipsychotic AgentsAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsMethylphenidateAdolescentAmphetamineChildDrug InteractionsHumansHyperkinesisMaleRisperidoneAmphetamineAntipsychotic AgentsCentral Nervous System StimulantsMethylphenidateRisperidone

Identifiers

PMID35489029
PMCPMC9060383
OpenAlexW4225140230

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.